What is the role of Hydroxychloroquine (HCQ) in managing autoimmunity, particularly in patients with autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus?

Why Hydroxychloroquine is Given in Autoimmunity

Hydroxychloroquine (HCQ) is the backbone treatment for autoimmune diseases, particularly systemic lupus erythematosus, because it provides multiple immunomodulatory effects that reduce disease activity, prevent organ damage, decrease infection and thrombosis risk, and improve survival—all while maintaining a favorable safety profile compared to traditional immunosuppressants. 1

Mechanisms of Immunomodulation

HCQ works through several distinct cellular pathways that collectively dampen the hyperactive immune response characteristic of autoimmune diseases:

• HCQ accumulates in acidic intracellular vesicles (lysosomes and endosomes), raising their pH and inhibiting pH-dependent enzymes, which disrupts multiple inflammatory cascades 2, 3

• The drug blocks Toll-like receptor (TLR) signaling in endosomes, preventing the recognition of self-antigens (like DNA and RNA) that trigger autoimmune responses 4, 3

• HCQ inhibits antigen processing and presentation, reducing the activation of autoreactive T cells 2, 3

• Production of pro-inflammatory cytokines (TNF-α and IL-6) is significantly reduced, which directly addresses the inflammatory cascade driving tissue damage in autoimmune conditions 2, 3

• Autophagy modulation occurs, affecting how cells process and present self-antigens 3

The FDA label acknowledges that while HCQ has established anti-inflammatory and immunomodulatory effects in rheumatoid arthritis and lupus, the complete mechanisms are not fully elucidated 5

Clinical Benefits Beyond Immunomodulation

HCQ is distinguished from traditional immunosuppressants because it provides disease control without causing generalized immunosuppression, making it safer for long-term use 2

The 2024 EULAR systematic review confirmed multiple beneficial outcomes in SLE patients:

• Reduced mortality with a pooled hazard ratio of 0.46 for death 1
• Prevention of disease flares and reduced organ damage accrual 1
• Decreased thrombosis risk, particularly important in antiphospholipid antibody-positive patients 6
• Lower infection rates despite being used for immune disease 1
• Improved cardiometabolic profile including hypolipidemic and hypoglycemic effects 6, 7
• Steroid-sparing effects, allowing reduction of glucocorticoid doses and their associated toxicities 6

Disease-Specific Applications

Systemic Lupus Erythematosus

All patients with SLE should receive HCQ unless absolute contraindications exist, as it is considered the foundation of lupus therapy 1, 8

• HCQ contributes to lupus nephritis remission when combined with other immunosuppressants 6
• The drug prevents lupus flares during pregnancy and reduces adverse pregnancy outcomes 6
• Long-term continuation rates are significantly higher in SLE (76% at 24 months) compared to rheumatoid arthritis (46% at 24 months), reflecting its superior efficacy in lupus 9

Rheumatoid Arthritis

• HCQ improves joint inflammation and reduces cardiometabolic risk 1, 6
• It is commonly used as part of combination DMARD therapy, particularly with methotrexate and sulfasalazine 1
• Discontinuation rates are higher in RA due to inadequate disease control rather than toxicity 9

Other Autoimmune Conditions

• Sjögren's syndrome: Improves lacrimal quality and both objective and subjective inflammatory markers 6
• Antiphospholipid syndrome: Effective for primary and secondary thrombosis prevention 6
• Dermatomyositis, sarcoidosis, and Still disease: May provide benefit for specific manifestations 6

Dosing to Maximize Benefit While Minimizing Risk

The maximum safe dose is ≤5 mg/kg actual body weight per day, which keeps retinopathy risk below 2% over 10 years 10

• Starting doses are typically 200-400 mg daily for SLE 10
• Doses below 5 mg/kg may be inadequate, as lower doses (2-3 mg/kg/day) are associated with higher flare rates 10
• Dose reduction of 25% is required when eGFR <30 mL/min/1.73 m², as renal impairment is the greatest modifiable risk factor for toxicity 10

Critical Safety Monitoring

The primary concern with long-term HCQ use is retinal toxicity, which requires structured screening:

• Baseline ophthalmologic examination within the first few months of therapy 10
• Annual screening beginning after 5 years for low-risk patients 10
• Annual screening beginning after 1 year for high-risk patients (those with eGFR <60, concomitant tamoxifen use, or pre-existing retinal disease) 10
• East Asian patients require screening beyond the central macula due to different retinopathy phenotype 10

Other safety considerations include:

• Baseline ECG due to QT prolongation risk, though six studies found no clinically relevant QTc prolongation with standard HCQ use 1
• G6PD testing in men of African, Asian, or Middle Eastern origin before starting therapy due to hemolysis risk 10
• The 2024 EULAR review found no major safety signals beyond retinal toxicity when used at appropriate doses 1

Common Pitfalls to Avoid

• Do not use ideal body weight for dosing calculations—actual body weight should be used, as retinopathy risks were similar across BMI groups when actual weight was used 10
• Do not discontinue HCQ casually in SLE patients—discontinuation is associated with disease flares, and the goal is safe long-term maintenance 1, 9
• Do not fail to adjust for renal impairment—this is the greatest modifiable risk factor for toxicity 10
• Do not accept inadequate disease control without treatment escalation—if breakthrough symptoms occur on HCQ alone, add other DMARDs or biologics rather than accepting suboptimal outcomes 8